Home
About
Back
About
Contact Us
Meet the Team
Back
Senior Leadership
Board of Directors
Scientific Advisory Board
History of Providence
Foundations of Providence
Careers & Culture
Technology
Back
mRNA Medicines Ecosystem
mRNA Medicines Platform
INTENT (TM) LNP Platform
Manufacturing Platform
Pipeline
Business Development
Back
Partnerships
Contact
News & Media
Back
Press Releases
Publications
Media
Culture
Back
Careers
Golf Tournament
Home
About
About
Contact Us
Meet the Team
Senior Leadership
Board of Directors
Scientific Advisory Board
History of Providence
Foundations of Providence
Careers & Culture
Technology
mRNA Medicines Ecosystem
mRNA Medicines Platform
INTENT (TM) LNP Platform
Manufacturing Platform
Pipeline
Business Development
Partnerships
Contact
News & Media
Press Releases
Publications
Media
Culture
Careers
Golf Tournament
Publications
and Scientific Papers
All
2025
2024
2023
2022
INTENT™ LNPs Induce Effective Anti-Tumor T cell Responses
Read more
An INTENT™ LNP Reagent for Targeted mRNA Transfection of Dendritic Cells and Macrophages
Read more
Process development of tangential flow filtration and sterile filtration for manufacturing of mRNA-lipid nanoparticles: A study on membrane performance and filtration modeling
Read more
Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice
Read more
A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection
Read more
Therapeutic mRNA cancer vaccine for GBM reaches complete response in a pre-clinical model
Read more
Comparison of modified T7 RNAPs to develop a simplified, cost effective, robust mRNA production process
Read more
Novel LNP delivered mRNA vaccine elicits potent immune responses and cures established tumor in mice
Read more
Next-Generation LNP's Induce Effective Anti-Tumor T cell Responses
Read more
Next-Generation mRNA-LNP Vaccine Prototype Achieves Tumor Clearance in a GBM Mouse Model
Read more
Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study
Read more
Phase I randomized, observer‑blinded, placebo‑controlled study of a SARS‑CoV‑2 mRNA vaccine PTX‑COVID19‑B
Read more
In vivo Characterization of T-Cell Activating Disulfide Lipids
Read more
Preclinical Evaluation of a SARS-CoV-2 mRNA Vaccine PTX-COVID19-B
Read more